Terms ending in 2038
Bayer Pharma Aktiengesellschaft
Every in-force patent on Bayer Pharma Aktiengesellschaft's record whose computed term ends in 2038, whoever holds it now. Soonest term end first, then patent number.
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 11,142,522 | Compounds, Compositions and Methods for Cancer Treatment In force · High confidence | Bayer Aktiengesellschaft and Bayer Pharma Aktiengesellschaft | In force | High confidence | |
| US 11,795,164 | 2-Heteroaryl-3-OXO-2,3-Dihydropyridazine-4-Carboxamides for the Treatment of Cancer In force · Medium confidence | Deutsches Krebsforschungszentrum | In force | Medium confidence | |
| US 12,522,594 | 2-Heteroaryl-3-OXO-2,3-Dihydropyridazine-4-Carboxamides for the Treatment of Cancer In force · Medium confidence | Deutsches Krebsforschungszentrum | In force | Medium confidence | |
| US 11,691,986 | Ptefb Inhibiting Macrocyclic Compounds In force · Medium confidence | Bayer Aktiengesellschaft and Bayer Pharma Aktiengesellschaft | In force | Medium confidence | |
| US 11,976,334 | Inhibitor of Atr Kinase for Use in a Method of Treating a Hyper-Proliferative Disease In force · Medium confidence | Bayer Aktiengesellschaft and Bayer Pharma Aktiengesellschaft | In force | Medium confidence | |
| US 11,684,621 | Combination Containing SGC Stimulators and Mineralocorticoid Receptor Antagonists In force · Medium confidence | Bayer Pharma Aktiengesellschaft | In force | Medium confidence | |
| US 11,433,140 | Specific Antibody Drug Conjugates (ADCS) Having KSP Inhibitors In force · High confidence | Bayer Pharma Aktiengesellschaft | In force | High confidence | |
| US 11,098,063 | Diazabicyclic Substituted Imidazopyrimidines and Their Use for the Treatment of Breathing Disorders In force · High confidence | Bayer Aktiengesellschaft and Bayer Pharma Aktiengesellschaft | In force | High confidence | |
| US 11,208,422 | Substituted Bridged Diazepane Derivatives and Use Thereof as TASK-1 and TASK-3 Inhibitors In force · High confidence | Bayer Pharma Aktiengesellschaft | In force | High confidence | |
| US 12,053,476 | Compounds, Compositions and Methods for Cancer Patient Stratification and Cancer Treatment In force · Medium confidence | Bayer Pharma Aktiengesellschaft | In force | Medium confidence | |
| 20 more term ends in 2038 · Pro | |||||
10 of 30 patents shown. Soonest term end first, then patent number.
Pro members see all 30.
22 of these are in force and held by Bayer Pharma Aktiengesellschaft.
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.